|Writing Group Member||Employment||Consultant||Speaker||Ownership/Partnership/Principal||Research||Institutional, Organizational, or Other Financial Benefit||Expert Witness|
|Sidney C. Smith, Jr, Chair||Center for Cardiovascular Science and Medicine—Professor of Medicine; Director||None||None||None||None||None||None|
|Spencer B. King III, Co-Chair||Saint Joseph's Heart and Vascular Institute—President; Saint Joseph's Health System—Executive Director, Academic Affairs||Medtronic⁎MLV Therapeutics||Network for Continuing Medical Education⁎||None||Abbott; AngelMed; BG Medicine; Merck||None||None|
|Jeffrey L. Anderson||Intermountain Medical Center—Associate Chief of Cardiology||BMS/Sanofi-aventis; Daiichi-Sankyo; Eli Lilly||None||None||None||None||None|
|Steven R. Bailey||University of Texas Medical Center—Professor of Medicine and Radiology||Volcano Therapeutics||Abbott; BSCI; Cordis; Medtronic; Volcano Therapeutics||None||Abbott; BSCI; Cordis; Volcano Therapeutics||SCAI Fellows Grant⁎||None|
|James C. Blankenship||Geisinger Medical Center—Director, Cardiology; Director, Cardiac Cath Lab||None||Sanofi-aventis||None||None||None||None|
|Alice K. Jacobs||Boston University School of Medicine—Professor of Medicine; Boston University Medical Center—Director, Cardiac Catheterization Laboratories and Interventional Cardiology||None||None||None||Abbott Vascular; Accumetrics; Cordis; Schering-Plough Research Institute||None||None|
|Douglass A. Morrison||Yakima Heart Center—Interventional Cardiologist||None||None||None||None||None||None|
|Eric D. Peterson||Duke Clinical Research Institute, Duke University Medical Center—Professor of Medicine; Director, Cardiovascular Research||None||None||None||Bristol-Myers Squibb/Sanofi-aventis⁎; Merck⁎; Schering-Plough⁎||None||None|
|Patrick L. Whitlow||Cleveland Clinic Foundation, Dept. of Cardiovascular Medicine—Director, Interventional Cardiology||None||None||ICON Plc; Medlogics; Medtronic||Edwards⁎; Evalve||None||None|
|David O. Williams||Brigham and Women's Hospital||Boston Biomedical (DSMB)⁎; Cordis||None||None||Volcano Therapeutics||None||None|
DSMB indicates data and safety monitoring board; SCAI, Society for Cardiovascular Angiography and Interventions.
This table represents the relationships of committee members with industry that were reported at the Task Force on Practice Guidelines meeting and updated in conjunction with all meetings. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity or ownership of $10 000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships noted in this table are modest unless otherwise noted.
↵⁎ Significant (greater than $10 000) relationship.